OSI Seeks Partner For DPP-4 Inhibitor Paused At Phase III Gate
This article was originally published in The Pink Sheet Daily
Executive Summary
OSI’s metabolic business unit Prosidion also aims to out-license its glucokinase activator candidate in the next three months, Prosidion president tells “The Pink Sheet” DAILY.
You may also be interested in...
Astellas Considers Options To Shed All Or Parts Of Diabetes Unit Prosidion
TOKYO - Astellas is weighing its options for metabolic subsidiary Prosidion, likely divesting all or part of it, as the company continues its integration, and shedding, of OSI Pharmaceuticals. If it sells off Prosidion, Astellas will be left with few pipeline entries in the diabetes space
OSI Pharmaceuticals President Colin Goddard: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Goddard talks about OSI’s metabolic syndrome pipeline, competing with Merck in the DPP-4 space and profitability.
OSI Pharmaceuticals President Colin Goddard: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Goddard talks about OSI’s metabolic syndrome pipeline, competing with Merck in the DPP-4 space and profitability.